UK On Cusp Of Value-Based Procurement With NHS Future Operating Model Going Live

The UK's complex system of procuring medical technology for use in the National Health Service is being simplified. A new system will go live on May 8 under the Future Operating Model (FOM), an initiative that prioritizes outcomes-based rationales and allows for gain-sharing, while also targeting annual NHS savings. At this early stage, the device industry and health-care providers are both displaying a mix of optimism and skepticism.

uk pound coins and uk flag

The UK's National Health Service Supply Chain contract ended andproposals from a government reviewto reduce cost variation in NHS England's secondary care setting signaled a need to rethink the complex and costly NHS procurement methods for medical technology. The plan that emerged, the Future Operating Model, is designed to save NHS money annually, but not in the transactional sense. Instead, it deploys value-based health-care concepts that are designed to yield sustainable benefits for patients, as well as the payer and provider. Also see "UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement" - Medtech Insight, 8 February, 2018.

FOM was the focus of an event hosted by the Association of British Healthcare Industries, the UK medtech industry association, in London on March 20. It was, as ABHI Chief Operating Officer Nishan Sunthares explained, the first ABHI procurement meeting in the past five years. But no better time to host another, given the huge changes coming. (See box, "UK FOM Go-Live Dates.") Not that much change will be evident immediately after May 8, the day when the six medical procurement "Category Towers" set up under the FOM will go live

Rationalization And Simplification Of NHS Procurement: A No-Brainer

The case for simplification of NHS procurement is made easily. There are 320,000 products in the Supply Chain catalog, yet the average Trust uses just over 9,000 of them

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.